Pursuant to Regulation 30, read with Clause 20 Para A of Part A of Schedule III, of SEBI Listing Regulations, Medplus Health Services has informed that one of its Subsidiary Company has received an order from Drugs and Control Authority. The detailed disclosure with respect to the order as required under the SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13 July 2023 is enclosed herewith as per Annexure A. The aforesaid information is also being placed on the website of the Company at www.medplusindia.com
The above information is a part of company’s filings submitted to BSE.
